新的ASCO/CAP乳腺癌激素受体检测指南建议建立标准操作程序(SOP),以确认或裁定雌激素受体(ER)结果具有弱或≤10%染色。以及0%至10%染色病例报告的内部对照(IC)状态。这项研究的目的是确定在SOP之后可能需要额外步骤的弱或≤10%染色的ER测试频率,并确定肿瘤激素受体状态与发现IC的可能性之间的任何相关性。纳入2014年1月至2019年4月的乳腺癌病例,以确定阴性,低阳性和弱阳性病例。IC的存在/不存在与肿瘤类型相关。遵循ASCO/CAP指南,29.8%的案例(374/1261)将需要额外的步骤来确认/裁定结果,低,或ER弱正状态。在ER和孕激素受体(PgR)阴性肿瘤的情况下,发现IC的可能性降低〜50%。由于缺乏IC,在所有病例的13.1%(92/700)中可能需要重复测试。总之,新的ASCO/CAP指南建议实验室建立并遵循SOP,在报告激素受体状态之前确认或裁定约30%病例的ER结果.超过40%的肿瘤ER阳性<10%的病例缺乏IC,可能需要根据指南进行评论,表明可能需要重复测试。然而,IC的存在/不存在可能与乳腺癌的亚型有关,不一定会质疑检测的有效性.
The new ASCO/CAP
guidelines on hormone receptor testing in breast cancer recommends standard operating procedures (SOPs) established to confirm or adjudicate estrogen receptor (ER) results with weak or ≤10% staining, and the status of internal controls (ICs) reported for cases with 0% to 10% staining. The aim of this study is to determine the frequency of ER testing with weak or ≤10% staining that may require additional steps following SOPs and to identify any correlation between hormone receptor status of the tumor and the likelihood of finding IC. Breast cancer cases between January 2014 and April 2019 were included to identify negative, low-positive and weak-positive cases. The presence/absence of IC was correlated to tumor type. Following ASCO/CAP
guidelines, 29.8% of cases (374/1261) will need additional steps to confirm/adjudicate results due to negative, low, or weak positive ER status. The probability of finding IC is ~50% lower in cases of ER and progesterone receptor (PgR) negative tumors. Repeat testing may be warranted in 13.1% (92/700) of all cases due to lack of IC. In conclusion, the new ASCO/CAP
guidelines recommend laboratories to establish and follow SOP to confirm or adjudicate ER results for about 30% of the cases before reporting hormone receptors status. Over 40% of cases with <10% tumor ER positivity lacked IC that may need a comment per the
guidelines indicating a repeat testing may be warranted. However, the presence/absence of IC may be related to the subtype of breast cancer and should not necessarily bring into question the validity of the test.